- Home
- CRDF vs FDMT Comparison
CRDF vs FDMT Comparison
Compare CRDF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- FDMT
- Stock Information
- Founded
- CRDF 1999
- FDMT 2013
- Country
- CRDF United States
- FDMT United States
- Employees
- CRDF N/A
- FDMT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- FDMT Health Care
- Exchange
- CRDF Nasdaq
- FDMT Nasdaq
- Market Cap
- CRDF 210.2M
- FDMT 192.2M
- IPO Year
- CRDF N/A
- FDMT 2020
- Fundamental
- Price
- CRDF $3.59
- FDMT $4.31
- Analyst Decision
- CRDF Strong Buy
- FDMT Buy
- Analyst Count
- CRDF 5
- FDMT 10
- Target Price
- CRDF $10.50
- FDMT $32.33
- AVG Volume (30 Days)
- CRDF 1.5M
- FDMT 511.6K
- Earning Date
- CRDF 08-07-2025
- FDMT 08-07-2025
- Dividend Yield
- CRDF N/A
- FDMT N/A
- EPS Growth
- CRDF N/A
- FDMT N/A
- EPS
- CRDF N/A
- FDMT N/A
- Revenue
- CRDF $587,000.00
- FDMT $23,000.00
- Revenue This Year
- CRDF N/A
- FDMT $13,048.65
- Revenue Next Year
- CRDF N/A
- FDMT N/A
- P/E Ratio
- CRDF N/A
- FDMT N/A
- Revenue Growth
- CRDF N/A
- FDMT N/A
- 52 Week Low
- CRDF $2.01
- FDMT $2.24
- 52 Week High
- CRDF $5.64
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- CRDF 57.14
- FDMT 57.27
- Support Level
- CRDF $3.07
- FDMT $3.68
- Resistance Level
- CRDF $3.24
- FDMT $4.13
- Average True Range (ATR)
- CRDF 0.24
- FDMT 0.28
- MACD
- CRDF -0.02
- FDMT -0.03
- Stochastic Oscillator
- CRDF 61.17
- FDMT 67.02
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.